Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
about
Non-steroid agents for idiopathic pulmonary fibrosisPirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapyPharmacological management of IPFPatient considerations and drug selection in the treatment of idiopathic pulmonary fibrosisNew perspectives on management of idiopathic pulmonary fibrosisRecent Treatments of Interstitial Lung Disease with Systemic SclerosisTreatment of rheumatoid arthritis-associated interstitial lung disease: a perspective reviewFibrotic and sclerotic manifestations of chronic graft-versus-host diseasePulmonary fibrosis: patterns and perpetratorsUpdate on diagnosis and treatment of idiopathic pulmonary fibrosisUpdate on therapeutic management of idiopathic pulmonary fibrosisAn official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and managementTime-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosisUbiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseFibrocytes and the pathogenesis of diffuse parenchymal lung disease.Evolving therapies for liver fibrosis.Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review.Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosisAdvances in the management of idiopathic pulmonary fibrosis.Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.Novel therapeutic approaches for pulmonary fibrosis.Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trialMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosisA Mathematical Model of Idiopathic Pulmonary Fibrosis.Idiopathic pulmonary fibrosis and cancer: do they really look similar?The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosisTreatment of idiopathic pulmonary fibrosis: a network meta-analysis.Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases.Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report.Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project.Molecular and cellular mechanisms of pulmonary fibrosis.Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.Current and novel drug therapies for idiopathic pulmonary fibrosis.Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation.
P2860
Q24235478-69FC9D0F-6234-475F-B395-40F89C9A43ACQ26738458-BF56A965-DB05-4F3B-82A8-72AC4A06509FQ26748808-166444C6-B880-4723-99F3-C468F63FE8E0Q26750418-2F7F117D-BF50-4E37-B59C-4B9C053EAF3FQ26765586-66224E26-FBCB-4155-AD9D-BCF6D383AB23Q26773161-A36A7ADE-ECD0-4EF8-81B1-422E58ABE0F4Q26775753-3B77F2AF-09D6-4FEE-8907-1E3B348F5220Q27024147-CE16FDAE-2417-403E-B80F-DB5FB6C46DF2Q27694249-936CDB5D-DA21-41B6-A764-8D32A6BF2966Q28083702-363AFCEE-FA49-4B0F-A253-C8AFB5BE2797Q28083944-31E0A2DD-AE6E-4636-9D24-3B64B269C4D3Q28308246-7EA4CDC4-EC34-4679-AFC1-58670731C53DQ28388130-47E4342D-6808-43FE-825F-CD4C11F99C14Q28395536-ECA121B2-40CA-47B5-95D1-6B3A23EE5E9BQ29620307-F488A94E-5FF4-40B6-8C73-FDBB2C05CD7CQ30426516-416A73E2-147C-4DED-A444-AFE71C332D32Q30539166-31DD8226-DC2C-41FA-B3D4-71ADE280A714Q33432312-46DEB58C-1F2C-4FA9-B9B2-DDDDC5F206AAQ33698776-DC7E9829-EDCA-4A2E-827E-3D5486247153Q33814226-0BD22D6A-3431-4804-8E32-50EB8A6DCFA5Q34026607-3FE57B85-5D3E-4B95-90AC-7247BEB89479Q34352802-80DB8C0D-5562-4709-AA2B-3397E6DEE0FAQ34432217-6B04E193-D633-43D7-A9AA-63494AD515C1Q34504710-DD6398F7-1684-4A89-9247-589B86774690Q34677487-5DDFEDA8-2CCA-4E8D-B929-E4A22D5FEFE3Q34903224-2B924F2B-6389-433D-A4C4-929983526EBDQ34906164-76330DFC-C975-4DD2-B652-70F731CC9D9BQ35558781-40320AA6-B3B3-4FB8-88FB-EC48C38AC73EQ35766783-FF2146A6-E34A-408D-8745-E7D60D1CB4BFQ35785589-EE6A3564-4E1A-46AF-B129-C84F85FCDDABQ35908863-CB46DBF6-2E17-4C35-A029-CBF0FF93592DQ35914125-B8D7C210-B73E-4032-B6A7-D6ACF91DC4A6Q36063833-15DF0122-A850-45D3-B26E-81315C549B3AQ36161839-6312677D-A135-4770-902A-42306EC4E49DQ36206673-2AF16077-6781-406F-BADD-4DBC502F2A4AQ36237168-4BC52FB3-776F-49CE-9122-85835B6C2FD5Q36264068-98716322-F72F-4542-85D7-3C93E3913812Q36294959-5972F7B9-AA01-4016-8875-5A3F21F13EFCQ36373463-8D4DEC50-8FC9-408C-A152-994A82423824Q36488760-4C3C9989-DF61-4715-BC2D-1D2A72246432
P2860
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Imatinib treatment for idiopat ...... cebo-controlled trial results.
@en
Imatinib treatment for idiopat ...... cebo-controlled trial results.
@nl
type
label
Imatinib treatment for idiopat ...... cebo-controlled trial results.
@en
Imatinib treatment for idiopat ...... cebo-controlled trial results.
@nl
prefLabel
Imatinib treatment for idiopat ...... cebo-controlled trial results.
@en
Imatinib treatment for idiopat ...... cebo-controlled trial results.
@nl
P2093
P1476
Imatinib treatment for idiopat ...... cebo-controlled trial results.
@en
P2093
Andrew H Limper
Craig E Daniels
Darrell R Schroeder
Edith Gabor
Imatinib-IPF Study Investigators
Joseph A Lasky
Kathleen Mieras
P304
P356
10.1164/RCCM.200906-0964OC
P407
P577
2009-12-10T00:00:00Z